**Abstract**

**Objective:** This 8-week, open-label, randomized, parallel study aimed to compare strategies differing in the speed of switching schizophrenia patients to aripiprazole from other antipsychotic agents, with dual administration for 2 weeks and then tapering off the current antipsychotic in fast (within 1 week) versus slow (within 4 weeks) strategies.

**Methods**: Patients with a primary DSM-IV diagnosis of schizophrenia or schizoaffective disorder were randomized to either the fast-switching (n=38) or slow-switching (n=41) group. Efficacy assessments at 5 time-points included Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression (CGI) scale. Drug concentrations and cytochrome P450 *CYP2D6* and *CYP3A4* genotypes were also measured.

**Results:** The fast- and slow-switching groups were comparable in demographical and clinical features at baseline and dropout rate. In the intention-to-treat analysis using mixed-effects models, there were significant within-group decreases over time in the PANSS total scores (p=0.03) and its subscores except for positive subscores, whereas no between-group differences were found. A reduction in body weight (p=0.01) and lower levels of total cholesterol (p=0.03), triglycerides (p=0.03), and prolactin (p=0.01) were noted in both groups, but no increase in extrapyramidal symptoms or prolongation of QT~C.~ The blood concentrations of aripiprazole in all patients were in a therapeutic range at day 56, with *CYP2D6\*10* polymorphisms being associated with aripiprazole concentrations. However, aripiprazole concentrations (days 14 and 28) were not correlated with change of the PANSS, SAS, AIMS scores. Furthermore, when the outcome was compared based on pre-switch antipsychotic agents (first-generation versus second-generation antipsychotics), there were no significant differences in efficacy or side-effect measures between the two groups.

**Conclusions:** There is no significant difference between fast- and slow-switching strategy in terms of improvements in clinical symptoms and metabolic profile in this 8-week study. This is in contrast to the usual recommendations by experts that slower switching is the preferred approach.
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